The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Origin and evolution of high throughput screening
Open accessAbstract
This article reviews the origin and evolution of high throughput screening (HTS) through the experience of an individual pharmaceutical company, revealing some of the mysteries of the early stages of drug discovery to the wider pharmacology audience. HTS in this company (Pfizer, Groton, USA) had its origin in natural products screening in 1986, by substituting fermentation broths with dimethyl sulphoxide solutions of synthetic compounds, using 96‐well plates and reduced assay volumes of 50‐100 μ l. A nominal 30m M source compound concentration provided high μM assay concentrations. Starting at 800 compounds each week, the process reached a steady state of 7200 compounds per week by 1989. Screening in the Applied Biotechnology and Screening Group was centralized with screens operating in lock‐step to maximize efficiency. Initial screens were full files run in triplicate. Autoradiography and image analysis were introduced for 125 I receptor ligand screens. Reverse transcriptase (RT) coupled with quantitative PCR and multiplexing addressed several targets in a single assay. By 1992 HTS produced ‘hits’ as starting matter for approximately 40% of the Discovery portfolio. In 1995, the HTS methodology was expanded to include ADMET targets. ADME targets required each compound to be physically detected leading to the development of automated high throughput LC‐MS. In 1996, 90 compounds/week were screened in microsomal, protein binding and serum stability assays. Subsequently, the mutagenic Ames assay was adapted to a 96‐well plate liquid assay and novel algorithms permitted automated image analysis of the micronucleus assay. By 1999 ADME HTS was fully integrated into the discovery cycle. British Journal of Pharmacology (2007) 152, 53–61; doi:10.1038/sj.bjp.0707373
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Potent Nonpeptide Antagonist of the Substance P (NK 1 ) Receptor
Snider, R. M., Constantine, J. W., Lowe, J. A., Longo, K. P., Lebel, W. S., Woody, H. A., Drozda, S. E., Desai, M. C., Vinick, F. J., Spencer, R. W., et al. (1991) · Science · doi:10.1126/science.1703323 · Cited by 859
Genes in S. cerevisiae encoding proteins with domains homologous to the mammalian ras proteins
Powers, S., Kataoka, T., Fasano, O., Goldfarb, M., Strathem, J., Broach, J., & Wigler, M. (1984) · Cell · doi:10.1016/0092-8674(84)90340-4 · Cited by 460
Functional homology of mammalian and yeast RAS genes
Kataoka, T., Powers, S., Cameron, S., Fasano, O., Goldfarb, M., Broach, J., & Wigler, M. (1985) · Cell · doi:10.1016/0092-8674(85)90304-6 · Cited by 318
Banker, M. J., Clark, T. H., & Williams, J. A. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10332 · Cited by 305
Self-citationMargolis, J. M., & Obach, R. S. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.606 · Cited by 135
Diversity screening versus focussed screening in drug discovery
Valler, M. J., & Green, D. V. S. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01517-8 · Cited by 130
High Throughput Screening: The Discovery of Bioactive Substances
Devlin, J. P. (1997) · Medical Entomology and Zoology · Cited by 107
Miniaturization technologies in HTS: how fast, how small, how soon?
Burbaum, J. J. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(98)01203-3 · Cited by 104
Novel miniaturized systems in high-throughput screening
Battersby, B. J., & Trau, M. (2002) · Trends in biotechnology · doi:10.1016/s0167-7799(01)01898-4 · Cited by 89
High Throughput Screening: Methods and Protocols
Janzen, W. P. (2002) · Cited by 77
Cited by
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
From DFT to machine learning: recent approaches to materials science–a review
Schleder, G. R., Padilha, A. C. M., Acosta, C. M., Costa, M., & Fazzio, A. (2019) · Journal of Physics: Materials · doi:10.1088/2515-7639/ab084b · Cited by 852
Self-Driving Laboratories for Chemistry and Materials Science
Tom, G., Schmid, S. P., Baird, S. G., Cao, Y., Darvish, K., Hao, H., Lo, S., Pablo-García, S., Rajaonson, E. M., Skreta, M., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00055 · Cited by 707
Novel trends in high-throughput screening
Mayr, L. M., & Bojanic, D. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.08.004 · Cited by 694
Transforming Environmental Health Protection
Collins, F. S., Gray, G. M., & Bucher, J. R. (2008) · Science · doi:10.1126/science.1154619 · Cited by 630
Metadata
- Authors
- Pereira, D. A., & Williams, J. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-09
- Volume
- 152
- Issue
- 1
- Pages
- 53-61
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2037849836
- Cited by
- 364
- References
- 13
- FWCI
- 17.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Origin and evolution of high throughput screening. https://app.cochat.ai/papers/10.1038/sj.bjp.0707373
- The paper
- Pereira, D. A., & Williams, J. A. (2007). Origin and evolution of high throughput screening. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.